APLE vs LXP

The deterministic health scores raise significant concerns, with a Piotroski F-Score of 4/9 indicating marginal financial health and no available Altman Z-Score, limiting bankruptcy risk assessment. Despite a seemingly attractive valuation with a Price/Book below 1 and a 7.7% dividend yield, the company faces declining earnings and revenue, a high payout ratio of 129.73%, and weakening profitability trends. Analysts recommend a buy, but recent earnings misses, deteriorating growth, and lack of insider buying undermine confidence. The stock trades above the Graham Number ($14.87) but well above its intrinsic value estimate of $5.11, suggesting overvaluation relative to fundamentals.

LXP exhibits a severe divergence between its current market price ($50.16) and its deterministic value markers, with a Piotroski F-Score of 4/9 indicating only marginal stability. The stock trades at a significant premium to both its Graham Number ($33.20) and its growth-based intrinsic value ($10.43). Fundamental deterioration is evident through negative YoY revenue and earnings growth, coupled with an unsustainable dividend payout ratio of 149.73%. Despite recent price appreciation, the technical trend is heavily bearish (10/100), suggesting a potential correction to align with poor underlying fundamentals.